Literature DB >> 21028850

The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.

Tam Luong Nguyen1, Xiaoming Xu, Rick Gussio, Arun K Ghosh, Ernest Hamel.   

Abstract

We used synthetic peloruside A for the commercial preparation of [³H]peloruside A. The radiolabeled compound bound to preformed tubulin polymer in amounts stoichiometric with the polymer's tubulin content, with an apparent K(d) value of 0.35 μM. A less active peloruside A analogue, (11-R)-peloruside A and laulimalide acted as competitive inhibitors of the binding of the [³H]peloruside A, with apparent K(i) values of 9.3 and 0.25 μM, respectively. Paclitaxel, epothilone B, and discodermolide had essentially no ability to inhibit [³H]peloruside A binding, confirming that these compounds bind to a different site on tubulin polymer. We modeled both laulimalide and peloruside A into the binding site on β-tubulin that was identified by Huzil et al. (J. Mol. Biol. 2008, 378, 1016-1030), but our model provides a more reasonable structural basis for the protein-ligand interaction. There is a more complete desolvation of the peloruside A ligand and a greater array of favorable hydrophobic and electrostatic interactions exhibited by peloruside A at its β-tubulin binding site. In addition, the protein architecture in our peloruside A binding model was suitable for binding laulimalide. With the generation of both laulimalide and peloruside A binding models, it was possible to delineate the structural basis for the greater activity of laulimalide relative to peloruside A and to rationalize the known structure-activity relationship data for both compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21028850      PMCID: PMC2996141          DOI: 10.1021/ci1002894

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  41 in total

1.  Refined structure of alpha beta-tubulin at 3.5 A resolution.

Authors:  J Löwe; H Li; K H Downing; E Nogales
Journal:  J Mol Biol       Date:  2001-11-09       Impact factor: 5.469

2.  Synthesis and biological evaluation of (-)-laulimalide analogues.

Authors:  Brian M Gallagher; Francis G Fang; Charles W Johannes; Marc Pesant; Martin R Tremblay; Hongjuan Zhao; Kozo Akasaka; Xiang-yi Li; Junke Liu; Bruce A Littlefield
Journal:  Bioorg Med Chem Lett       Date:  2004-02-09       Impact factor: 2.823

3.  Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity.

Authors:  Rubén M Buey; J Fernando Díaz; José M Andreu; Aurora O'Brate; Paraskevi Giannakakou; K C Nicolaou; Pradip K Sasmal; Andreas Ritzén; Kenji Namoto
Journal:  Chem Biol       Date:  2004-02

4.  Total synthesis of the microtubule stabilizing antitumor agent laulimalide and some nonnatural analogues: the power of Sharpless' asymmetric epoxidation.

Authors:  Anjum Ahmed; E Kate Hoegenauer; Valentin S Enev; Martin Hanbauer; Hanspeter Kaehlig; Elisabeth Ohler; Johann Mulzer
Journal:  J Org Chem       Date:  2003-04-18       Impact factor: 4.354

5.  Total synthesis of microtubule-stabilizing agent (-)-laulimalide.

Authors:  A K Ghosh; Y Wang; J T Kim
Journal:  J Org Chem       Date:  2001-12-28       Impact factor: 4.354

6.  Mutational analysis of the class I beta-tubulin gene in human breast cancer.

Authors:  Seiichi Hasegawa; Yasuo Miyoshi; Chiyomi Egawa; Makoto Ishitobi; Yasuhiro Tamaki; Morito Monden; Shinzaburo Noguchi
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

7.  Synthesis and biological evaluation of (-)-laulimalide analogues.

Authors:  Paul A Wender; Sayee G Hegde; Robert D Hubbard; Lei Zhang; Susan L Mooberry
Journal:  Org Lett       Date:  2003-09-18       Impact factor: 6.005

8.  The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.

Authors:  Donald E Pryor; Aurora O'Brate; Geoffrey Bilcer; J Fernando Díaz; Yuefang Wang; Yong Wang; Mikio Kabaki; M Katherine Jung; José M Andreu; Arun K Ghosh; Paraskevi Giannakakou; Ernest Hamel
Journal:  Biochemistry       Date:  2002-07-23       Impact factor: 3.162

9.  Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.

Authors:  Kylie A Hood; Lyndon M West; Berber Rouwé; Peter T Northcote; Michael V Berridge; St John Wakefield; John H Miller
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Microtubule-stabilizing agents based on designed laulimalide analogues.

Authors:  Susan L Mooberry; Deborah A Randall-Hlubek; Rachel M Leal; Sayee G Hegde; Robert D Hubbard; Lei Zhang; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

View more
  9 in total

1.  Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Authors:  Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T Northcote; Ernest Hamel; Paraskevi Giannakakou; John H Miller
Journal:  Mol Cancer Ther       Date:  2011-06-08       Impact factor: 6.261

Review 2.  Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Authors:  Melissa M Gajewski; Laleh Alisaraie; Jack A Tuszynski
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

3.  Characterizing the Epothilone Binding Site on β-Tubulin by Photoaffinity Labeling: Identification of β-Tubulin Peptides TARGSQQY and TSRGSQQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin.

Authors:  Adwait R Ranade; LeeAnn Higgins; Todd W Markowski; Nicole Glaser; Dmitry Kashin; Ruoli Bai; Kwon Ho Hong; Ernest Hamel; Gerhard Höfle; Gunda I Georg
Journal:  J Med Chem       Date:  2016-03-17       Impact factor: 7.446

4.  Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.

Authors:  Adrian Begaye; Shana Trostel; Zhiming Zhao; Richard E Taylor; David C Schriemer; Dan L Sackett
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

Review 5.  Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.

Authors:  Cristina C Rohena; Susan L Mooberry
Journal:  Nat Prod Rep       Date:  2014-03       Impact factor: 13.423

6.  Interactions of halichondrin B and eribulin with tubulin.

Authors:  Ruoli Bai; Tam Luong Nguyen; James C Burnett; Onur Atasoylu; Murray H G Munro; George R Pettit; Amos B Smith; Rick Gussio; Ernest Hamel
Journal:  J Chem Inf Model       Date:  2011-05-13       Impact factor: 4.956

7.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

8.  Chemically diverse microtubule stabilizing agents initiate distinct mitotic defects and dysregulated expression of key mitotic kinases.

Authors:  Cristina C Rohena; Jiangnan Peng; Tyler A Johnson; Phillip Crews; Susan L Mooberry
Journal:  Biochem Pharmacol       Date:  2013-02-08       Impact factor: 5.858

9.  Laulimalide induces dose-dependent modulation of microtubule behaviour in the C. elegans embryo.

Authors:  Megha Bajaj; Martin Srayko
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.